These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15668752)

  • 21. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remittive effects of intramuscular alefacept in psoriasis.
    Gordon KB; Langley RG
    J Drugs Dermatol; 2003 Dec; 2(6):624-8. PubMed ID: 14711140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis.
    Krueger GG
    J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():17-24. PubMed ID: 12795771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis.
    Feldman SR; Menter A; Koo JY
    Br J Dermatol; 2004 Feb; 150(2):317-26. PubMed ID: 14996104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alefacept.
    Frampton J; Wagstaff A
    Am J Clin Dermatol; 2003; 4(4):277-86; discussion 287. PubMed ID: 12680805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alefacept: a review of the literature and practical guidelines for management.
    Hodak E; David M
    Dermatol Ther; 2004; 17(5):383-92. PubMed ID: 15379773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.
    Lui H; Gulliver W; Tan J; Hong CH; Hull P; Shear NH; Paradiso-Hardy F; Bissonette R
    J Drugs Dermatol; 2012 Aug; 11(8):929-37. PubMed ID: 22859237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alefacept is well tolerated in patients with chronic plaque psoriasis.
    Gottlieb AB
    J Cutan Med Surg; 2004 Dec; 8 Suppl 2():14-9. PubMed ID: 15668751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of alefacept in the treatment of chronic plaque psoriasis.
    Gordon KB; Valentine J
    J Cutan Med Surg; 2004 Dec; 8 Suppl 2():3-9. PubMed ID: 15668749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alefacept therapy produces remission for patients with chronic plaque psoriasis.
    Krueger GG; Ellis CN
    Br J Dermatol; 2003 Apr; 148(4):784-8. PubMed ID: 12752139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Redefining clinical response in psoriasis: targeting the pathological basis of disease.
    Ortonne JP
    J Drugs Dermatol; 2004; 3(1):13-20. PubMed ID: 14964742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of the dermatology life quality index in clinical trials of biologics for psoriasis.
    Basra MK; Hussain S
    Chin J Integr Med; 2012 Mar; 18(3):179-85. PubMed ID: 22466941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Biologic therapy and psoriasis].
    Gamo R; López-Estebaranz JL
    Actas Dermosifiliogr; 2006; 97(1):1-17. PubMed ID: 16540046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alefacept, first biologic agent approved for treatment of psoriasis.
    Piascik P
    J Am Pharm Assoc (2003); 2003; 43(5):649-50. PubMed ID: 14626761
    [No Abstract]   [Full Text] [Related]  

  • 35. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
    Goffe B; Papp K; Gratton D; Krueger GG; Darif M; Lee S; Bozic C; Sweetser MT; Ticho B
    Clin Ther; 2005 Dec; 27(12):1912-21. PubMed ID: 16507377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.
    Gordon KB; Vaishnaw AK; O'Gorman J; Haney J; Menter A;
    Arch Dermatol; 2003 Dec; 139(12):1563-70. PubMed ID: 14676071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.
    Guenther L; Langley RG; Shear NH; Bissonnette R; Ho V; Lynde C; Murray E; Papp K; Poulin Y; Zip C
    J Cutan Med Surg; 2004; 8(5):321-37. PubMed ID: 15868311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy outcomes in patients using alefacept in the AWARE study.
    Landells I; Searles G; Bissonnette R; Shear NH; Vender R; Lui H
    J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S122-30. PubMed ID: 20053324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.
    Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF
    J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis.
    Krell J; Nelson C; Spencer L; Miller S
    J Am Acad Dermatol; 2008 Apr; 58(4):609-16. PubMed ID: 18262681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.